Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Despite widespread use of statins to reduce low-density lipoprotein cholesterol (LDL-C) and associated atherosclerotic cardiovascular risk, many patients do not achieve sufficient LDL-C lowering due to muscle-related side effects, indicating novel treatment strategies are required. Bempedoic acid (ETC-1002) is a small molecule intended to lower LDL-C in hypercholesterolemic patients, and has been previously shown to modulate both ATP-citrate lyase (ACL) and AMP-activated protein kinase (AMPK) activity in rodents. However, its mechanism for LDL-C lowering, efficacy in models of atherosclerosis and relevance in humans are unknown. Here we show that ETC-1002 is a prodrug that requires activation by very long-chain acyl-CoA synthetase-1 (ACSVL1) to modulate both targets, and that inhibition of ACL leads to LDL receptor upregulation, decreased LDL-C and attenuation of atherosclerosis, independently of AMPK. Furthermore, we demonstrate that the absence of ACSVL1 in skeletal muscle provides a mechanistic basis for ETC-1002 to potentially avoid the myotoxicity associated with statin therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 ETC-1002-CoA inhibits ACL and mediates β1-selective AMPK activation. Recombinant human ACL was incubated in the presence of the indicated concentrations of ETC-1002-CoA (a–c) or ETC-1002 (d), and (a) coenzyme A (CoA), (b) citrate or (c) ATP. Conversion of [14C]-citrate to [14C]-acetyl-CoA was measured in counts per minute (CPM). Recombinant human (e) AMPKα1β1γ1 and (f) AMPKα1β2γ1 complexes were incubated in the presence of the indicated concentrations of ETC-1002, ETC-1002-CoA, AMP or A-769622. (g) Structure of ETC-1002 and the biochemical reaction that generates ETC-1002-CoA acyl-CoA synthetase (ACS). ETC-1002-CoA/CoASH enzyme ACL kinetic analyses are single measures, and representative results from n=3 independent experiments shown; AMPK activity was determined by time-resolved fluorescence resonance energy transfer expressed as mean±s.e.m. of triplicate measures. (a) Ki calculated by Michaelis–Menten kinetic analysis.](https://figures.cochat.ai/paper-figures/02df10a0267b44eda297dc9dcee13726/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-1.jpg)
![Figure 2 Differentiation of ETC-1002 from the myotoxic effects of statins. [14C]-ETC-1002 (10 μM) conversion to [14C]-ETC-1002-CoA in human liver microsomes was determined in the presence of 30 μM unlabelled (a) monocarboxylic and (b) dicarboxylic saturated competitive fatty acid substrates. RH7777 cells were treated with negative control (Control) or Slc27a2 (ACSVL1) siRNA; n=6, for 48 h, and (c) ACSVL1 expression determined by western blot, and [14C]-ETC-1002-CoA synthesis determined; n=3. (d) Both control and Slc27a2 siRNA-treated RH7777 cells were treated with vehicle, ETC-1002 (30 μM) or atorvastatin (0.5 μM), and de novo cholesterol synthesis measured over 4 h; n=6 transfections. (e) Relative ACSVL1 expression in microsomes prepared from human liver, kidney and skeletal muscle (SkM). (f) ETC-1002-CoA synthetase activity in microsomes prepared from human liver and skeletal muscle; palmitate (10 μM) used as a positive control for skeletal muscle microsome viability. (g) ACSVL1 expression was measured in primary human hepatocytes and primary human skeletal muscle (SkM) cells by western blotting and expressed relative to β-actin. (h) Primary human myotubes were treated with vehicle (Veh.), simvastatin 10 μM (Simva), atorvastatin 10 μM (Atorva) or ETC-1002 100 μM in the presence of [14C]-glucose for 12 h, and incorporation into non-saponifiable lipids determined; or treated with 0.1–100 μM simvastatin, atorvastatin or ETC-1002 for 48 h and (i) cytotoxicity was measure by GF-AFC/bis-AAF-R110 cleavage, and (j) Caspase 3,7 activity (DEVD cleavage) determined. Data for myotube cytotoxicity assays are expressed as mean±s.e.m., n=2 performed in triplicate. Data for liver (n=50 donors pooled) and kidney (n=50 donors pooled) microsome preparations are representative of two independent experiments performed in duplicate, and expressed as mean±s.d. Data for human skeletal muscle microsomes (n=4 pooled donors) are the mean±s.e.m. of two independent experiments performed in triplicate. Multiple comparisons were made using an one-way ANOVA, Bonferroni's multiple comparisons test; *P<0.05.](https://figures.cochat.ai/paper-figures/aa53cfde988849fa938e4aa3379a9671/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-2.jpg)


![Figure 5 ACL suppression increases LDLR. (a) Primary human hepatocytes were treated with vehicle or ETC-1002 (100 μM) for 18 h in the presence of [3H]-H2O or pretreated with the indicated concentrations of ETC-1002 for 1 h, following a 3 h [14C]-acetate pulse. Counts incorporated into the non-saponifiable (sterols), and saponifiable (fatty acids) lipid fractions were determined and expressed as % vehicle. (b) Primary human hepatocytes were treated with vehicle, atorvastatin (0.5 μM) or ETC-1002 (100 μM) for 36 h and total intracellular cholesterol concentrations were determined in cell lysates. (c) Media was assayed for apoB by enzyme-linked immunosorbent assay. (d) PHHs were treated with ETC-1002 for the indicated time points and the apoB concentrations were measured in the media. (e) PHH were pre-labelled overnight with [14C]-oleate and the effects of ETC-1002 treatment on oleate-derived counts in the media determined at the indicated time points. PHH hepatocytes were treated with ETC-1002 and atorvastatin, and (f) mRNA levels for HMGR, SREBF2, PCSK9 and LDLR were determined by reverse transcription–quantitative PCR or (g) LDL receptor activity determined; A-769662 (10 μM). (h) RH7777 cells were treated with the indicated concentrations of ETC-1002 or atorvastatin (0.5 μM), and [14C]-lactate incorporation into cholesterol (Chol), cholesteryl esters (CE) and triglycerides determined. (i) LDLR-mediated DiI–LDL uptake in response to the indicated concentrations of ETC-1002±atorvastatin (0.5 μM). RH7777 cells were subjected to negative control (NC) or Acly siRNA-mediated gene silencing (n=3) and analysed for (j) ACL LDLR protein levels, or (k) LDLR-mediated DiI–LDL uptake. Data for PHH are expressed as mean±s.e.m. of n=2 donors performed in triplicate (a–c,f,g; except A-769662 treatment was 1 donor) or representative of two independent experiments showing similar results (d,e). (h) IC50 and (i) EC50 determinations were made using nonlinear curve fit model. Multiple comparisons were made using (a,j,k) unpaired Student's t-test or (b,c,f,g) an one-way ANOVA, Bonferroni's multiple comparisons test; *P<0.05.](https://figures.cochat.ai/paper-figures/bdd7bd8103b34bfd9b8c72b35fad6960/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-5.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bempedoic acid is a pro-drug that reduces cholesterol synthesis by inhibiting adenosine triphosphate (ATP) citrate lyase, with very limited musculoskeletal-related side effects.280”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [280]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081 · cited 1×
“Triacsin C is a potent inhibitor of ACSL1 and 4, and a weak inhibitor of ACSVL1 (refs 43–47).”
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834 · cited 1×
“Upregulation of the LDL receptor results in a new homeostatic state, where more cellular cholesterol is derived from blood LDL particles, thus reducing blood LDL-C 51–53 .”
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
Mihaylova, M. M., & Shaw, R. J. (2011) · Nature Cell Biology · doi:10.1038/ncb2329 · Cited by 2,923
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Steinberg, G. R., & Kemp, B. E. (2009) · Physiological Reviews · doi:10.1152/physrev.00011.2008 · Cited by 1,637 · cited 1×
“Indeed, AMPK signalling has been shown to regulate some SREBP isoforms through phosphorylation 32 .”
Self-citationEfficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443 · cited 1×
“Myalgia (muscle pain, cramping and/or weakness) constitutes the most common adverse effect associated with statin treatment and often results in dose limitations, poor compliance or even discontinuation 10,11 .”
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
Schachter, M. (2005) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00299.x · Cited by 1,211 · cited 1×
“Statins lower LDL-C by inhibiting hepatic 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, the rate-limiting enzyme in the cholesterol biosynthesis pathway 6 .”
Cool, B., Zinker, B., Chiou, W., Kifle, L., Cao, N., Perham, M., Dickinson, R., Adler, A., Gagne, G., Iyengar, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.005 · Cited by 925
Fullerton, M. D., Galic, S., Marcinko, K., Sikkema, S., Pulinilkunnil, T., Chen, Z.-P., O'Neill, H. M., Ford, R. J., Palanivel, R., O'Brien, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3372 · Cited by 893 · cited 1×
“Changes in the rates of liver lipogenesis and fatty acid oxidation are important determinants in controlling liver lipid content 50 .”
Self-citationCarling, D., Zammit, V. A., & Hardie, D. G. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80292-2 · Cited by 599 · cited 1×
“However, we have also demonstrated that ETC-1002 treatment increased AMP-activated protein kinase (AMPK) 26 , a metabolic sensor capable of catalysing regulatory phosphorylation of numerous substrates that affect inflammatory signalling and lipid metabolism 31–39 .”
Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta, S., Paoletti, R., & Corsini, A. (2004) · Circulation · doi:10.1161/01.cir.0000131519.15067.1f · Cited by 578 · cited 1×
“Myalgia (muscle pain, cramping and/or weakness) constitutes the most common adverse effect associated with statin treatment and often results in dose limitations, poor compliance or even discontinuation 10,11 .”
Bilheimer, D. W., Grundy, S. M., Brown, M. S., & Goldstein, J. L. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.13.4124 · Cited by 557 · cited 1×
“This inhibition leads to reduced hepatic cholesterol levels, which triggers the upregulation of LDL receptors (LDLR) resulting in increased LDL particle clearance from the blood 7–9 .”
AMPK: a metabolic gauge regulating whole-body energy homeostasis
Lage, R., Diéguez, C., Vidal-Puig, A., & López, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.09.007 · Cited by 505
AMPK and the biochemistry of exercise: implications for human health and disease
Richter, E. A., & Ruderman, N. B. (2009) · Biochemical Journal · doi:10.1042/bj20082055 · Cited by 481
Acyl-CoA Metabolism and Partitioning
Grevengoed, T. J., Klett, E. L., & Coleman, R. A. (2014) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071813-105541 · Cited by 440 · cited 1×
“Although the specific physiological roles of many ACS isoforms remain unknown, their respective substrate specificities, subcellular localization and tissue expression profiles have been extensively characterized 41,42 .”
AMPK inhibition in health and disease
Viollet, B., Horman, S., Leclerc, J., Lantier, L., Foretz, M., Billaud, M., Giri, S., & Andreelli, F. (2010) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2010.488215 · Cited by 383 · cited 1×
“However, we have also demonstrated that ETC-1002 treatment increased AMP-activated protein kinase (AMPK) 26 , a metabolic sensor capable of catalysing regulatory phosphorylation of numerous substrates that affect inflammatory signalling and lipid metabolism 31–39 .”
AMP-activated protein kinase: new regulation, new roles?
Carling, D., Thornton, C., Woods, A., & Sanders, M. J. (2012) · Biochemical Journal · doi:10.1042/bj20120546 · Cited by 379
AMP-Activated Protein Kinase: A Target for Drugs both Ancient and Modern
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.08.019 · Cited by 372
AMP-Activated Protein Kinase in the Heart: Role During Health and Disease
Arad, M., Seidman, C. E., & Seidman, J. G. (2007) · Circulation Research · doi:10.1161/01.res.0000258446.23525.37 · Cited by 362
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., & Wiviott, S. D. (2015) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2015.08.004 · Cited by 360
Galic, S., Fullerton, M. D., Schertzer, J. D., Sikkema, S., Marcinko, K., Walkley, C. R., Izon, D., Honeyman, J., Chen, Z.-P., van Denderen, B. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58577 · Cited by 342
Self-citationBohula, E. A., Giugliano, R. P., Cannon, C. P., Zhou, J., Murphy, S. A., White, J. A., Tershakovec, A. M., Blazing, M. A., & Braunwald, E. (2015) · Circulation · doi:10.1161/circulationaha.115.018381 · Cited by 340
Zhou, J., Lhoták, S., Hilditch, B. A., & Austin, R. C. (2005) · Circulation · doi:10.1161/01.cir.0000160864.31351.c1 · Cited by 290 · cited 1×
“Following perfusion fixation with 10% neutral buffered formalin 65,66 , hearts (including the aortic roots) were cut transversely and embedded in paraffin.”
Self-citationRegulation of adipocyte gene expression in differentiation and syndromes of obesity/diabetes.
Spiegelman, B. M., Choy, L., Hotamisligil, G. S., Graves, R. A., & Tontonoz, P. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53107-0 · Cited by 277 · cited 1×
“Upregulation of the LDL receptor results in a new homeostatic state, where more cellular cholesterol is derived from blood LDL particles, thus reducing blood LDL-C 51–53 .”
Expression and Characterization of Recombinant Rat Acyl-CoA Synthetases 1, 4, and 5
Kim, J.-H., Lewin, T. M., & Coleman, R. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010793200 · Cited by 252
Pinkosky, S. L., Filippov, S., Srivastava, R. A. K., Hanselman, J. C., Bradshaw, C. D., Hurley, T. R., Cramer, C. T., Spahr, M. A., Brant, A. F., Houghton, J. L., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m030528 · Cited by 239
Self-citationZhou, J., Møller, J., Danielsen, C. C., Bentzon, J., Ravn, H. B., Austin, R. C., & Falk, E. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0901.096582 · Cited by 216
Self-citationSREBPs: Transcriptional Mediators of Lipid Homeostasis
HORTON, J. D., GOLDSTEIN, J. L., & BROWN, M. S. (2002) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2002.67.491 · Cited by 215
Wang, Q., Jiang, L., Wang, J., Li, S., Yu, Y., You, J., Zeng, R., Gao, X., Rui, L., Li, W., et al. (2009) · Hepatology · doi:10.1002/hep.22774 · Cited by 213 · cited 1×
“Suppression of ACL activity leads to a reduction in cytosolic acetyl-CoA, a required precursor for cholesterol and fatty acid synthesis 26 , and subsequent compensatory LDL receptor upregulation 20,24,25,55,56 .”
Hall, A. M., Smith, A. J., & Bernlohr, D. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306575200 · Cited by 191
Ballantyne, C. M., Davidson, M. H., MacDougall, D. E., Bays, H. E., DiCarlo, L. A., Rosenberg, N. L., Margulies, J., & Newton, R. S. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.050 · Cited by 175
Self-citationAMPK β1 Deletion Reduces Appetite, Preventing Obesity and Hepatic Insulin Resistance
Dzamko, N., van Denderen, B. J. W., Hevener, A. L., Jørgensen, S. B., Honeyman, J., Galic, S., Chen, Z.-P., Watt, M. J., Campbell, D. J., Steinberg, G. R., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.056762 · Cited by 175
Self-citationTreatment strategies in patients with statin intolerance: the Cleveland Clinic experience
Mampuya, W. M., Frid, D., Rocco, M., Huang, J., Brennan, D. M., Hazen, S. L., & Cho, L. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.06.004 · Cited by 173 · cited 1×
“An estimated 2–7 million patients in the United States have stopped statin treatment due to muscle complaints despite being at risk for cardiovascular disease 12,13 .”
Gutierrez, M. J., Rosenberg, N. L., MacDougall, D. E., Hanselman, J. C., Margulies, J. R., Strange, P., Milad, M. A., McBride, S. J., & Newton, R. S. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.302677 · Cited by 170
Self-citationSteinberg, S. J., Wang, S. J., Kim, D. G., Mihalik, S. J., & Watkins, P. A. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0510 · Cited by 164 · cited 1×
“Importantly, the tissue expression profile of ACSVL1 has been independently studied in mice and shown to be restricted to liver and kidney while absent in other tissues, including skeletal muscle 48 .”
Horn, C. G. V., Caviglia, J. M., Li, L. O., Wang, S., Granger, D. A., & Coleman, R. (2005) · Biochemistry · doi:10.1021/bi047721l · Cited by 164 · cited 1×
“Triacsin C is a potent inhibitor of ACSL1 and 4, and a weak inhibitor of ACSVL1 (refs 43–47).”
Statin Therapy for Primary Prevention of Cardiovascular Disease
Taylor, F. C., Huffman, M. D., & Ebrahim, S. B. J. (2013) · JAMA · doi:10.1001/jama.2013.281348 · Cited by 161 · cited 2×
“Pharmacological inhibition of cholesterol biosynthesis leads to effective lowering of elevated LDL-C, a validated biomarker for ASCVD risk reduction in hyperlipidemic patients 3–5 .”
Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance
Thompson, P. D., Rubino, J., Janik, M. J., MacDougall, D. E., McBride, S. J., Margulies, J. R., & Newton, R. S. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.03.003 · Cited by 159 · cited 1×
“…cholesterol synthesis, ETC-1002 significantly lowers elevated levels of LDL-C in hypercholesterolemic patients by 30% as monotherapy, up to an additional 24% when added on to stable statin therapy and up to 50% when combined with ezetimibe, suggestive of a distinct mechanism for LDL lowering 27–30 .”
Self-citationThe role of ATP citrate-lyase in the metabolic regulation of plasma lipids
PEARCE, N. J., Yates, J. W., Berkhout, T. A., Jackson, B., Tew, D. G., Boyd, H., Camilleri, P., Sweeney, P. J., Gribble, A. D., Shaw, A. N., et al. (1998) · Biochemical Journal · doi:10.1042/bj3340113 · Cited by 144 · cited 2×
“Early discovery strategies that focused on synthesizing citrate and citryl-CoA analogues yielded compounds that were highly potent in cell-free systems; however, they did not advance to clinical development largely due to poor cell permeability and insufficient bioavailability 24,25 .”
Self-citationJohnson, T. E., Zhang, X. D., Bleicher, K. B., Dysart, G. R., Loughlin, A. F., Schaefer, W. H., & Umbenhauer, D. R. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.04.010 · Cited by 144
Mendis, S. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.01.001 · Cited by 140 · cited 1×
“A n elevated level of plasma low-density lipoprotein cholesterol (LDL-C) is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), the leading cause of death and disability in the western world 1,2 .”
Molecular clues into the pathogenesis of statin‐mediated muscle toxicity
Baker, S. K. (2005) · Muscle & Nerve · doi:10.1002/mus.20291 · Cited by 137
Hoeg, J. M., & Brewer, H. B. (1987) · PubMed · Cited by 118
3-Hydroxy-3-Methylglutaryl—Coenzyme A Reductase Inhibitors in the Treatment of Hypercholesterolemia
Hoeg, J. M. (1987) · JAMA · doi:10.1001/jama.1987.03400240064025 · Cited by 96
Jia, Z., Pei, Z., Maiguel, D. A., Toomer, C. J., & Watkins, P. A. (2007) · Journal of Molecular Neuroscience · doi:10.1007/s12031-007-0038-z · Cited by 93 · cited 1×
“Although the specific physiological roles of many ACS isoforms remain unknown, their respective substrate specificities, subcellular localization and tissue expression profiles have been extensively characterized 41,42 .”
Osaki, Y., Nakagawa, Y., Miyahara, S., IWASAKI, H. O., Ishii, A., Matsuzaka, T., Kobayashi, K., Yatoh, S., Takahashi, A., Yahagi, N., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.09.065 · Cited by 89 · cited 1×
“…pathophysiology of statin-induced myalgia is not completely understood, significant evidence supports that it is linked to HMG-CoA reductase inhibition in skeletal muscle resulting in reduced production of one or more biological intermediates important to maintain normal muscle cell function 14–19 .”
Berkhout, T. A., Havekes, L. M., Pearce, N. J., & Groot, P. H. E. (1990) · Biochemical Journal · doi:10.1042/bj2720181 · Cited by 79 · cited 2×
“Although ACL is not rate limiting, its strategic position at the intersection of lipid and carbohydrate metabolism, and its potential to regulate lipoprotein metabolism, attracted early interest as a drug target to treat dyslipidemia 20–23 .”
Self-citationNeeded: Pragmatic Clinical Trials for Statin-Intolerant Patients
Maningat, P. D., & Breslow, J. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1112023 · Cited by 77 · cited 1×
“An estimated 2–7 million patients in the United States have stopped statin treatment due to muscle complaints despite being at risk for cardiovascular disease 12,13 .”
Wang, Q. A., Li, S., Jiang, L., Zhou, Y., Li, Z., Shao, M., Li, W., & Liu, Y. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m003335 · Cited by 70
Matzno, S., Yasuda, S., Juman, S., Yamamoto, Y., Nagareya-Ishida, N., Nakabayashi, T., Matsuyama, K., & Tazuya-Murayama, K. (2005) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.57.11.0014 · Cited by 59 · cited 1×
“…from the myotoxic effects of statins by showing that the absence of ACSVL1 expression in human skeletal muscle precludes ETC-1002 from inhibiting the cholesterol biosynthesis pathway, a critical source of important biological intermediates essential to maintain normal muscle cell function 14–18 .”
Possible Mechanisms Underlying Statin-Induced Skeletal Muscle Toxicity in L6 Fibroblasts and in Rats
Itagaki, M., Takaguri, A., Kano, S., Kaneta, S., Ichihara, K., & Satoh, K. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08238fp · Cited by 57
A live-cell high-throughput screening assay for identification of fatty acid uptake inhibitors
Li, H., Black, P. N., & Dirusso, C. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.09.025 · Cited by 54
Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies
Taha, D. A., de Moor, C. H., Barrett, D. A., & Gershkovich, P. (2014) · Translational research · doi:10.1016/j.trsl.2014.01.013 · Cited by 52 · cited 7×
“The [ 14 C] acetyl-CoA signal was detected (5min per well) in a TopCount NXT liquid scintillation counter (Perkin-Elmer, Waltham, MA).”
InfluentialThe Role of Early LDL Lowering to Prevent the Onset of Atherosclerotic Disease
Ference, B. A., & Mahajan, N. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0312-1 · Cited by 45 · cited 2×
“A n elevated level of plasma low-density lipoprotein cholesterol (LDL-C) is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), the leading cause of death and disability in the western world 1,2 .”
Singh, A. B., Kan, C. F. K., Dong, B., & Liu, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.696872 · Cited by 40 · cited 1×
“54), other effects on lipid metabolism resulting from loss of AMPK b 1 or ETC-1002 treatment cannot be ruled out.”
IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease
Catapano, A. L., & Ference, B. A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.008 · Cited by 36 · cited 1×
“Importantly, each of these mechanisms primarily reduces LDL-C by upregulating the activity of the LDLR, a mechanism proven to reduce cardiovascular events 60–62 .”
A novel direct homogeneous assay for ATP citrate lyase
Ma, Z., Chu, C.-H., & Cheng, D. (2009) · Journal of Lipid Research · doi:10.1194/jlr.d900008-jlr200 · Cited by 35
Gribble, A. D., Ife, R. J., Shaw, A. N., McNair, D., Novelli, C. E., Bakewell, S., Shah, V. P., Dolle, R. E., Groot, P. H. E., Pearce, N., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980091z · Cited by 34 · cited 2×
“Early discovery strategies that focused on synthesizing citrate and citryl-CoA analogues yielded compounds that were highly potent in cell-free systems; however, they did not advance to clinical development largely due to poor cell permeability and insufficient bioavailability 24,25 .”
Self-citationApolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs.
van Vlijmen, B. J. M., Pearce, N. J., Bergö, M. O., Staels, B., Yates, J. W., Gribble, A. D., Bond, B. C., Hofker, M. H., Havekes, L. M., & Groot, P. H. E. (1998) · PubMed · Cited by 31
Self-citationVessey, D. A., Kelley, M., & Warren, R. S. (2004) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.20009 · Cited by 29
Dolle, R. E., McNair, D., Hughes, M. J., Kruse, L. I., Eggelston, D., SAXTY, B. A., Wells, T. N. C., & Groot, P. H. E. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00104a014 · Cited by 24
Self-citationImmunohistochemical Detection of the Unfolded Protein Response in Atherosclerotic Plaques
Lhoták, Š., Zhou, J., & Austin, R. C. (2011) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-385116-1.00002-9 · Cited by 18 · cited 1×
“Serial sections, 4 m m thick, were cut starting from the aortic root origin and collected for measurement of lesion size (haematoxylin and eosin staining) and immunohistochemical analyses 67 .”
Self-citationDolle, R. E., Gribble, A., Wilkes, T., Kruse, L. I., Eggleston, D. S., SAXTY, B. A., Wells, T. N. C., & Groot, P. H. E. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00003a016 · Cited by 18
Self-citationRole of statin pleiotropism in acute coronary syndromes and stroke.
Liao, J. K. (2003) · PubMed · Cited by 17
Bilheimer, D. W., Grundy, S. M., Brown, M. S., & Goldstein, J. L. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.025 · Cited by 7
Ballantyne, C. M., MacDougall, D. E., Margulies, J. R., Robinson, P. L., Hanselman, J. C., & Lalwani, N. D. (2015) · Circulation · doi:10.1161/circ.132.suppl_3.17499 · Cited by 4 · cited 1×
“5i), and in support of our clinical findings, the addition of ETC-1002 to atorvastatin increased LDL receptor activity above atorvastatin treatment alone 29 , supporting that the co-suppression of ACL and HMG-CoA reductase activity is complementary (Fig.”
Self-citation
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
New insights into activation and function of the AMPK
Steinberg, G. R., & Hardie, D. G. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00547-x · Cited by 1,006
Self-citationBempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2215024 · Cited by 988
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807
Self-citation
Metadata
- Authors
- Pinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., Steinberg, G. R., & Lalwani, N. D.
- Affiliations
- Esperion Therapeutics (United States) (US)
- McMaster University (CA)
- St. Joseph’s Healthcare Hamilton (CA)
- Corresponding author
- Pinkosky, Stephen L.
- Steinberg, Gregory R.
- Venue
- Nature Communications
- Published
- 2016-11-28
- Volume
- 7
- Issue
- 1
- Pages
- 13457-13457
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5133702
- OpenAlex
- W2558991743
- Cited by
- 498
- References
- 73
- Citations by year
- 2026: 63 · 2025: 50 · 2024: 76 · 2023: 79 · 2022: 55 · 2021: 67 · 2020: 50 · 2019: 24 · 2018: 21 · 2017: 10 · 2016: 1
- FWCI
- 21.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- Amgen
- Heart and Stroke Foundation of Canada
- McMaster University
- Esperion Therapeutics
- Amgen Canada
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- bempedoic acid, ATP citrate lyase, LDL cholesterol lowering, atherosclerosis, prodrug activation, LDL receptor upregulation, AMPK, hypercholesterolemia, skeletal muscle
- MeSH terms
- Adenylate Kinase, Animals, ATP Citrate (pro-S)-Lyase, Dicarboxylic Acids, Enzyme Activation, Enzyme Inhibitors, Fatty Acids, Humans, Cholesterol, LDL, Liver, Mice, Inbred C57BL, Models, Biological, Organ Specificity, Receptors, LDL, Up-Regulation, Mice, Knockout, Disease Progression, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hepatocytes, Atherosclerosis, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.